Risperidone: A pharmacoeconomic review of its use in schizophrenia

PharmacoEconomics

Volumn 14, Issue 1, 1998, Pages 97-133

  Foster, Rachel H ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; OLANZAPINE; PERPHENAZINE; RISPERIDONE; ZUCLOPENTHIXOL;

ANXIETY NEUROSIS; COGNITION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UTILIZATION; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HUMAN; INSOMNIA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCHIZOPHRENIA; TACHYCARDIA; VERTIGO;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA;

EID: 0031872936     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814010-00009     Document Type: Review

References (168)

1. Cohen LJ. Looking beyond the formulary budget in cost-benefit analysis. Am J Manage Care 1997 Feb; 3 (Special report) Suppl.: S11-7
2. Gutierrez-Esteinou R, Grebb JA. Risperidone: an analysis of the first three years in general use. Int Clin Psychopharmacol 1997 Sep; 12 Suppl. 4: S3-S10
3. Glazer WM. Clinical outcomes of pharmacotherapy for schizophrenia and implications for health economics. J Clin Psychiatry Monogr Ser 1997 Feb; 15: 22-3
4. Viale GL. Evaluating the cost effectiveness of newer psychotropic medications. Am J Manage Care 1997 Feb; 3 (Special report) Suppl.: S7-S10
5. Lindström E. The hidden cost of schizophrenia. J Drug Dev Clin Pract 1996 Jan; 7: 281-8
6. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21 (3): 419-29
7. Fleischhacker WW, Meise U, Günther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994; 89 Suppl. 382: 11-5
8. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association, 1994
9. Andreasen NC. Assessment issues and the cost of schizophrenia. Schizophr Bull 1991; 17 (3): 475-81
10. Diagnostic and statistical manual of mental disorders: DSM-III-R. 3rd revised ed. Washington, DC: American Psychiatric Association, 1987
11. Prudo R, Blum HM. Five-year outcome and prognosis in schizophrenia: a report from the London Field Research Centre of the International Pilot Study of Schizophrenia. Br J Psychiatry 1987; 150: 345-54
12. Knapp M, Kavanagh S. Economic outcomes and costs in the treatment of schizophrenia. Clin Ther 1997 Jan-Feb; 19: 128-38
13. Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study VIII. Five-year follow-up: clinical and psychosocial findings. Br J Psychiatry 1992; 161: 496-500
14. Ginsberg G, Shani S, Lev B. Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel. Pharmacoeconomics 1998 Feb: 13 (2): 231-41
15. Daniels BA, Kirkby KC, Hay DA, et al. Predictability of rehospitalisation over 5 years for schizophrenia, bipolar disorder and depression. Aust N Z J Psychiatry 1998; 32: 281-6
16. Rupp A, Keith SJ. The costs of schizophrenia. Assessing the burden. Psychiatr Clin North Am 1993 Jun; 16: 413-23
17. Frankenburg FR, Hegarty JD. Cost considerations in the treatment of schizophrenia. CNS Drugs 1996 Jan; 5: 75-82
18. Brown S. Excess mortality of schizophrenia. Br J Psychiatry 1997; 171: S02-8
19. Tabbane K, Joober R, Spadone C, et al. Mortality and causes of death in schizophrenia: a review [in French]. Encephale 1993 Jan/Feb; 19: 23-8
20. Awad AG, Voruganti LNP, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997 Jan; 11: 32-47
21. Capri S. Methods for evaluation of the direct and indirect costs of long-term schizophrenia. Acta Psychiatr Scand 1994; 89 Suppl. 382: 80-3
22. Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia: implications for the post-institutional era in the US. Pharmacoeconomics 1995 Sep; 8: 199-222
23. Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 1997; 58 Suppl. 10: 50-4
24. Larson LN. Cost determination and analysis. In: Bootman JL, Townsend RJ, McGhan WF, editors. Principles of pharmacoeconomics. 2nd ed. Cincinnati: Harvey Whitney Books Company, 1996: 44-59. N
25. Rouillon F, Toumi M, Dansette G-Y. Some aspects of the cost of schizophrenia in France. Pharmacoeconomics 1997 Jun; 11: 578-94
26. Evers SM, Ament AJ. Costs of schizophrenia in The Netherlands. Schizophr Bull 1995; 21: 141-53
27. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994 Nov; 165 Suppl. 25: 18-21
28. Knapp M. Costs of schizophrenia. Br J Psychiatry 1997; 171: 509-18
29. Rice DP, Miller LS. The economic burden of schizophrenia. Paper presented at the Sixth Biennial Research Conference on the Economics of Mental Health; 1992 Sep 21-22; Bethesda (MD), USA
30. Wyatt RJ, Henter I, Leary MC, et al. An economic evaluation of schizophrenia - 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30: 196-205
31. Viale GL. Looking beyond the formulary budget: introduction. Am J Manage Care 1997; 3 (Special report) Suppl.: S5-6
32. Genduso LA, Castelli Haley J. Cost of illness studies for schizophrenia: components, benefits, results, and implications. Am J Manage Care 1997 Jun; 3 (6): 873-7
33. Suleiman TG, Ohaeri JU, Lawal RA, et al. Financial cost of treating out-patients with schizophrenia in Nigeria. Br J Psychiatry 1997 Oct; 171: 364-8
34. Wasylenki DA. The cost of schizophrenia. Can J Psychiatry 1994 Nov; 39 Suppl. 2: S65-9
35. National Advisory Mental Health Council. Health care reform for Americans with severe mental illnesses: report of the National Advisory Mental Health Council. Am J Psychiatry 1993 Oct; 150: 1447-65
36. Rice DP, Kelman S, Miller LS. The economic burden of mental illness. Hosp Community Psychiatry 1992 Dec; 43 (12): 1227-32
37. Langley-Hawthorne C. Modeling the lifetime costs of treating schizophrenia in Australia. Clin Ther 1997; 19 (6): 1470-95
38. Grant S, Filton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994 Aug; 48: 253-73
39. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997 Oct; 17: 407-18
40. Peuskens J. Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995 Jun; 166: 712-26
41. Huttunen MO, Piepponen T, Rantanen T, et al. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995 Apr; 91: 271-7
42. Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993 Dec; 88: 395-402
43. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994 Jun; 151: 825-35
44. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993 Feb; 13: 25-40
45. Jeste DV, Klausner M, Brecher M, et al. A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. Psychopharmacology 1997 Jun; 131: 239-47
46. Mosby's complete drug reference: physicians GenRx. 7th ed. St Louis: Mosby-Year Book, Inc. 1997
47. Love RC, Conley RR, Kelly KL, et al. Risperidone dosing trends in the Maryland State Mental Health System [poster], 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 Dec 8-12; Kameula, Hawaii
48. Work Group on Schizophrenia Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997 Apr; 154 Suppl.: 1-63
49. Kopala LC. Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr Scand 1996; 94 Suppl. 389: 12-7
50. Lindström E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995 May-Jun; 17: 402-12
51. Möller H-J, Gagiano CA, Addington DE, et al. Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. Int Clin Psychopharmacol In press
52. Bennett JA, Stanton SP, Wilson DR, et al. Clinical predictors of acute risperidone response in elderly patients with schizophrenia and schizoaffective illnesses [abstract]. Psychopharmacol Bull 1996; 32 (3): 412
53. Zarate CA Jr, Baldessarini RJ, Siegel AJ, et al. Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry 1997 Jul; 58: 311-7
54. Berman I, Merson A, Rachov-Pavlov, et al. Risperidone in elderly schizophrenic patients. An open-label study. Am J Geriatr Psychiatry 1996; 4 (2): 173-9
55. Aronson SM, Lingam V, Stack M. Risperidone in the treatment of elderly psychiatric patients [poster]. American Medical Directors Association 19th Annual Symposium; 1996 Mar 7-10: New Orleans
56. Gierz M, An A, Linda L, et al. Use of risperidone in the elderly [poster]. 9th Annual Meeting of the American Association for Geriatric Psychiatry; 1996 Feb 16-19; Tuscon
57. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995 Nov; 56: 514-8
58. Lacro JP, Eastham JH, Gilbert P, et al. Risperidone treatment in older patients with psychoses [poster]. Annual Meeting of the American College of Clinical Pharmacy; 1996 Aug 4-7; Nashville
59. Madhusoodanan S, Brecher M, Brenner R, et al. Efficacy and tolerability of risperidone in elderly patients with psychotic disorders [poster]. American Association for Geriatric Psychiatry Annual Meeting; 1907 Mar 2-5; Lake Buena Vista (FL), USA
60. Davidson M. The Risperidone Working Group. Long-term efficacy, safety and tolerability of risperidone in elderly psychotic patients: a 3-month interim analysis [poster]. 8th Congress of the International Psychogeriatric Association; 1997 Aug 17-22; Jerusalem
61. Linden M, Albus M, Klauder CA, et al. Risperidone and elderly patients with schizophrenia: interim results of a german post marketing surveillance study [poster]. 8th Congress of the International Psychogeriatric Association; 1997 Aug 17-22; Jerusalem
62. Greevich SJ, Findling RL, Rowane WA, et al. Risperidone in the treatment of children and adolescenls with schizophrenia: a retrospective study. J Child Adolesc Psychopharmacol 1996; 6 (4): 251-7
63. Lykes WC, Cueva JE. Risperidone in children with schizophrenia. J Am Acad Child Adolesc Psychiatry 1996 Apr; 35: 405-6
64. Quintana H, Keshavan M. Case study: risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 1995 Oct; 34: 1292-6
65. Cosgrove F. Recent advances in paediatric psychopharmacology [letter]. Hum Psychopharm 1994 Sep-Oct; 9: 381-2
66. Cozza SJ, Edison DL. Risperidone in adolescents [letter]. J Am Acad Child Adolesc Psychiatry 1994 Oct; 33: 1211
67. Armenteros JL, Whitaker AH, Welikson M, et al. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 1997 May; 36: 694-700
68. Fleurot O, Bech P, Turjanski S, et al. Amisulpride versus risperidone in the treatment of acute schizophrenia [abstract]. Biol Psychiatry 1997 Jul 1; 42 Suppl.: 194S
69. Heinrich K, Klieser E, Lehmann E, et al. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog Neuropsych Biol Psychiatry 1994 Jan; 18: 129-37
70. Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998 Apr; 155 (4): 499-504
71. Schooler NR. Comments on article by Tran and colleagues, "Double-Clind Comparison of Olanzapine Versus Risperidone in Treatment of Schizophrenia and Other Psychotic Disorders" [letter]. J Clin Psychopharmacol 1998 Apr; 18 (2): 174-5
72. Tollefson GD, Tran PV. Comments on article by Tran and colleagues, "Double-Blind Comparison of Olanzapine Versus Risperidone in Treatment of Schizophrenia and Other Psychotic Disorders". Reply [letter]. J Clin Psychopharmacol 1998 Apr; 18 (2): 175-6
73. Gheuens J, Grebb JA. Comments on article by Tran and associates, "Double-Blind Comparison of Olanzapine Versus Risperidone in Treatment of Schizophrenia and Other Psychotic Disorders" [letter]. J Clin Psychopharmacol 1998 Apr; 18 (2): 176-7
74. Tollefson GD, Tran PV. Comments on article by Tran and associates, "Double-Blind Comparison of Olanzapine Versus Risperidone in Treatment of Schizophrenia and Other Psychotic Disorders". Reply [letter]. J Clin Psychopharmacol 1998 Apr; 18 (2): 177-9
75. Davies A, Adena MA, Keks NA, et al. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin Ther 1998; 20 (1): 58-71
76. Schotte A, Van Baelen B. Treatment of the symptoms of schizophrenia: a meta-analysis comparing risperidone with other antipsychotic agents [poster]. 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7-13; Davos, Switzerland
77. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997 Dec; 58 (12): 538-46
78. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta analysis. Int Clin Psychopharmacol 1995 Nov; 10: 207-13
79. Möller HJ, Müller H, Borison RL, et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995 Mar; 245: 45-9
80. Keefe RSE, Mohs RC, Losonczy MF, et al. Characteristics of very poor outcome schizophrenia. Am J Psychiatry 1987 Jul; 144 (7): 889-95
81. Buchanan RW, Gold JM. Negative symptoms: diagnosis, treatment and prognosis. Int Clin Psychopharmacol 1996 May; 11 Suppl. 2: 3-11
82. Mahmoud RA, Engelhart LM, Oster G, et al. Risperidone vs. conventional antipsychotics: a prospective randomized naturalistic effectiveness trial of outcomes in chronic schizophrenia [poster]. 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 Dec 8-12; Kameula, Hawaii
83. Buckley PF, Donenwirth K, Bayer KE, et al. Risperidone for treutment-resistant schizophrenia: initial clinical experience in a state hospital. J Pharm Technol 1996 Nov-Dec; 12: 271-5
84. Avnon M, Kunin A. Risperidone response after no clozapine response [letter]. Br J Psychiatry 1995 Nov; 167: 699
85. Chouinard G, Vainer JL, Belanger MC, et al. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog Neuropsych Biol Psychiatry 1994 Nov; 18: 1129-41
86. Smith RC, Chua JW, Lipetsker B, et al. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J Clin Psychiatry 1996 Oct; 57: 460-6
87. Warner JP, Gledhill JA, Wakeling A. The use of risperidone in treatment-resistant schizophrenia: two case reports. Int Clin Psychopharmacol 1996 Mar; 11: 65-6
88. Keck PE Jr, Wilson DR, Strakowski SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995 Oct; 56: 466-70
89. Mercer G, Murray C, Rogers A, et al. Treatment resistant schizophrenia: preliminary findings with risperidone [abstract]. Eur Psychiatry 1994; 9 Suppl. 1: 84S
90. Cavallaro R, Brambilla P, Smeraldi E. The sequential treatment approach to resistant schizophrenia with risperidone and clozapine: results of an open study with follow-up. Hum Psychopharm 1998; 13: 91-7
91. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996 Sep; 57: 395-7
92. Still DJ, Dorson PG, Crismon ML. Effects of risperidone in clozapine-treated schizophrenic patients [abstract]. Psychopharmacol Bull 1995; 31 (3): 623
93. Lacey RL, Preskorn SH, Jerkovich GS. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics. Am J Psychiatry 1995 Sep; 152: 1401
94. Tanner TB, Ganguli R, Reddy R, et al. Risperidone for treatment-refractory schizophrenia [letter]. Am J Psychiatry 1995 Aug; 152: 1233
95. Sevy S, Davidson M. The cost of cognitive impairment in schizophrenia. Schizophr Res 1995 Sep; 17: 1-3
96. Borison RL. The role of cognition in the risk-benefit and safety analysis of antipsychotic medication. Acta Psychiatr Scand 1996; 94 Suppl. 389: 5-11
97. Gallhofer B, Bauer U, Lis S, et al. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996; 6 Suppl. 2: 13-20
98. Sharma T, Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol 1998; 18 (2 Suppl. 1): 12S-9S
99. Tune LE, Strauss ME, Lew MF, et al. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982 Nov; 139 (11): 1460-2
100. Calev A. Anti-cholinergic drugs and memory [letter]. Br J Psychiatry 1983; 143: 422-3
101. Rossi A, Mancini F, Stratta P, et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 1997 Jan; 95: 40-3
102. Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 1996 Oct; 41 Suppl. 2: S35-40
103. Addington J, Addington D. Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol [letter]. Can J Psychiatry 1997 Nov; 42: 983
104. Williams R, Dickson R, Caliguiri M, et al. Improvement in tardive dyskinesia, laterality of TD and cognition in schizophrenic patients changed from typical neuroleptics in [sic] risperidone [abstract no. P-4-83]. Eur Neuropsychopharmacol 1995 Sep; 5 (Spec. Is.): 352
105. Wirshing WC, Ames D, Marder SR, et al. Risperidone vs. haloperidol in treatment-resistant schizophrenia: preliminary results [abstract]. Schizophr Res 1996; 18 (2/3): 130
106. Foster Green M, Marshall Jr BD, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997 Jun; 154: 799-804
107. Berman I, Merson A, Allan B, et al. Effect of risperidone on cognitive performance in elderly schizophrenic patients: a double-blind comparison study with haloperidol [abstract]. Psychopharmacol Bull 1995; 31 (3): 552
108. Goldberg TE, Daniel DG, Pickar D, et al. A comparison of risperidone and typical neuroleptics: effects on neurocognition [poster]. American College of Neuropsychopharmacology 33rd Annual Meeting; 1994 Dec 12-16; San Juan, Peurto Rico
109. Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 1992 Mar; 43: 262-5
110. Keks NA. Minimizing lhe non-extrapyramidal side-effects of antipsychotics. Acta Psychiatr Scand 1996; 94 Suppl. 389: 18-24
111. Van Putten I. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974 Jul; 31: 67-72
112. Simpson GM, Lindenmayer J-P. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997; 17 (3): 194-201
113. Brecher M, Lemmens P, Van Baelen B. Tolerability and cardiovascular safety of risperidone [poster]. Annual Meeting of the American College of Neuropsychiatry; 1996 Dec 9-13; San Juan, Puerto Rico
114. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian Multicenter Risperidone Study. J Clin Psychopharmacol 1995 Feb; 15 Suppl. 1: 36S-44S
115. Khan BU. Risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. J Autism Dev Disord 1497; 27 (4): 479-89
116. Santone G, Cotani P, Giuliani S, et al. Tardive dyskinesia remission during risperidone therapy [case report]. Clin Drug Invest 1997 Dec; 14 (6): 502-6
117. Daniel DG, Goldberg TE, Weinberger DR, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996 Mar; 153: 417-9
118. Barcia D, Ayuso JL, Herraiz ML, et al. Calidad de vida en pacientes esquizofrénicos tratados con risperídona. An Psiquiatr 1996; 12 (10): 403-12
119. Negrón AE, Leiderman EA, Parkadavil M. A naturalistic outcome study of risperidone treatment among state hospital patients. Psychiatr Serv 1996 Oct; 47: 1118-20
120. Amery W, Zuiderwijk P, Brecher M, et al. Safety profile of risperidone [poster]. 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 Dec 8-12; Kameula, Hawaii
121. Kleinberg DL, Brecher M, Davis JM. Prolactin levels and adverse events in patients treated with risperidone [poster]. 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego
122. Janssen Pharmaceutica Inc. Risperdal® (risperidone) prescribing information. Titusville (NJ), USA, 1997 Oct
123. Lieberman JA, Alvir JMaJ. A report of clozapine-induced agranulocytosis in the United States. Incidence and risk factors. Drug Saf 1992; 7 Suppl. 1: 1-2
124. British National Formulary. Number 34 (September 1997). London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 1997
125. Revicki DA, Murray M. Assessing health-related quality of life outcomes of drug treatments for psychiatric disorders. CNS Drugs 1994 Jun; 1: 465-76
126. Awad AG, Voruganti LNP, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res 1997 Jan; 6: 21-6
127. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992; 22: 347-52
128. Bobes J, Gutiérrez M, Gibert J, et al. Long-term evolution of the SF-36 (8 months) in a sample of 353 schizophrenic patients undergoing risperidone treatment [abstract no. 125]. Qual Life Res 1997; 6: 650
129. Brescan DW, Ramirez LF. Effect of risperidone on quality of life [abstract no 46]. Qual Life Res 1997; 6: 626
130. Hasanah CI, Razali SM. The role of novel antipsychotics in improving the quality of life in schizophrenic patients [abstract no. 144]. Qual Life Res 1997; 6: 655
131. Franz M, Lis S, Plüddemann K, et al. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997 May; 170: 422-5
132. Agarwal MR. Subjective quality of life in schizophrenia [letter]. Br J Psychiatry 1997 Oct; 171: 392
133. Huybrechts K. Outcomes assessment is schizophrenia: methodological issues. Schizophr Rev 1996 (Aug); 4 Suppl. 3: 2-3
134. Kaiser W, Priebe S, Barr W, et al. Profiles of subjective quality of life in schizophrenic in- and out-patient samples. Psychiatry Res 1997 Feb 7; 66: 153-66
135. Albright PS, Livingstone S, Keegan DL, et al. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan Health Linkable Databases. Clin Drug Invest 1996 May; 11: 289-99
136. Carter C, Stevens M, Durkin M. Effects of risperidone therapy on the use of mental health care resources in Salt Lake County, Utah. Clin Ther 1998; 20 (2): 352-63
137. Finley PR, Summer BR, Corbitt JL, et al. Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull 1998; 34 (1): 75-81
138. Lacro JP, Vonderscher CN, Kodsi AB, et al. Cost analysis of risperidone in veterans with schizophrenia or schizoaffective disorder. Annual Meeting of the New Clinical Drug Evaluation Unit; 1997 May 27-30; Boca Raton (FL), USA
139. Philipp M, Risperidone Study Group. Risperidone in patients which schizophrenia: acute responses and effects on one-year hospitalization rates [poster]. 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York
140. Viale G, Mechling L, Maislin G, et al. Impact of risperidone on the use of mental health care resources. Psychiatr Serv 1997 Sep; 48: 1153-9
141. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993 Sep-Oct; 15: 917-26
142. Guest JF, Hart WM, Cookson RF, et al. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Econ 1996; 10: 59-67
143. Rosenheck R, Massari L, Frisman L. Who should receive high-cost mental health treatment and for how long? Schizophr Bull 1993; 19 (4): 843-52
144. Nightengale BS, Garrett L, Waugh S, et al. Economic outcomes associated with the use of risperidone in a naturalistic group practice setting. Am J Manage Care 1998 Mar; 4 (3): 360-6
145. Javitt SC, Negron A, Sigler L. Retrospective analysis of the effect of risperidone on clinical outcome. Am J Manage Care 1997 Feb; 3 (Special report) Suppl.: S18-26
146. Chengappa KNR, Sheth S, Brar JS, et al. A clinical audit of the first 142 patients who received risperidone at a state psychiatric hospital. Annual Meeting of the New Clinical Drug Evaluation Unit; 1997 May 27-30; Boca Raton (FL), USA
147. Conley RL, Love RC, Kelly DL, et al. Rehospitalization rate of recently discharged patients treated with risperidone [poster]. 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 Dec 8-12; Kameula, Hawaii
148. LeLorier J, Petersen T, Albright PS. A retrospective cohort study of the RAMQ database to study the impact of risperidone use in the province of Quebec [abstract]. 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego
149. Nightengale BS, Crumly JM, Liao J, et al. Economic outcomes of antipsychotic agents in a Medicaid population; traditional agents vs. risperidone. Janssen Pharmaceutica (Titusville, NJ). 1998 (Data on file)
150. Hart WM, Lindström E, Guest JF. Economic impact of the use of risperidone for the treatment of chronic schizophrenia in Ireland. Ir J Psychiatry 1997 Spr/Sum; 16 (3): 12-6
151. Thompson D. Cost of switching from neuroleptics to risperidone and clozapine; a pilot study of the San Diego County Mental Health Services. Clin Drug Invest 1997 Nov; 14: 428-33
152. Albus M, Klauder CA, Linden M, et al. Dosing risperidone in daily practice: interim results of a German postmarketing surveillance study [poster]. 6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France
153. Sheldon TA. Problems of using models in the economic evaluation of health care. Health Econ 1996 Jan-Feb; 5 (1): 1-11
154. Glazer WM, Ereshefsky L. A pharmacoeconomic model of out-patient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 1996 Aug; 57: 337-45
155. Post HA, van Hout BA. Cost effectiveness of olanzapine in comparison to risperidone and haloperidol [abstract]. 13th Annual Meeting of the International Society Technology Assessment Health Care; 1997 May 25-28; Barcelona, Spain, 134
156. Chan Y-C, Votolato NA, Nasrallah HA. Pharmacoeconomic comparisons of risperidone and olanzapine during acute in-patient treatment of schizophrenia [poster]. 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 Dec 8-12; Kameula, Hawaii
157. Procyshyn R et al. Drug utilisation patterns and outcomes associated with in-hospital treatment with risperidone and olanzapine [abstract]. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto
158. Davies A, Langley PC, Keks NA, et al. Risperidone versus haloperidol: II. Cost-effectiveness. Clin Ther 1998; 20 (1): 196-213
159. Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997 Aug; 17: 298-307
160. Oh P, Einarson TR, Iskedjian M, et al. Pharmacoeconomic evaluation in schizophrenia: clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997 Jul
161. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993 Jan; 162: 38-42
162. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996; 57 Suppl. 9: 66-76
163. Glennie JL. Technology Overview: Pharmaceuticals. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Ottawa: Canadian Co-ordinating Office for Health Technology Assessment, 1997 Jul
164. Mattes JA. Risperidone: how good is the evidence for efficacy? Schizophr Bull 1997; 23 (1): 155-61
165. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994 Sep 8; 331: 650-5
166. Adityanjee, Pelonero AL. Prescribing risperidone [letter]. Psychiatr Serv 1995 Mar; 46: 291-2
167. Rationing of clozapine and risperidone. Pharm J 1996 Apr 13; 256: 513
168. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146 (4): 473-81